News
CYTH
2.170
-2.69%
-0.060
Cyclo Therapeutics to Present at the China NPC Association Meeting
GAINESVILLE, Fla., August 08, 2022--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and fami...
Business Wire · 1d ago
Cyclo Therapeutics to Present at the NNPDF-INPDA Conferences 2022
GAINESVILLE, Fla., July 21, 2022--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and famili...
Business Wire · 07/21 12:05
We're A Little Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 07/12 11:30
Cyclo Therapeutics to Present at the World Orphan Drug Congress USA 2022
GAINESVILLE, Fla., July 11, 2022--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and famili...
Business Wire · 07/11 12:05
Cyclo Therapeutics to Present at the 2022 NPC Patient and Family Conference Hosted by the Australian NPC Disease Foundation
GAINESVILLE, Fla., June 21, 2022--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and famili...
Business Wire · 06/21 12:05
Top Premarket Gainers
MT Newswires · 05/25 08:08
Cyclo Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
GAINESVILLE, Fla., May 18, 2022--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a late clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and fa...
Business Wire · 05/18 12:00
Cyclo Therapeutics GAAP EPS of -$0.33 beats by $0.14, revenue of $0.19M misses by $0.36M
Cyclo Therapeutics press release (NASDAQ:CYTH): Q1 GAAP EPS of -$0.33 beats by $0.14. Revenue of $0.19M (-47.2% Y/Y) misses by $0.36M.
Seekingalpha · 05/12 20:56
BRIEF-Cyclo Therapeutics Reports First Quarter 2022 Financial Results
reuters.com · 05/12 20:26
-- Earnings Flash (CYTH) CYCLO THERAPEUTICS Reports Q1 Loss $-0.33
MT Newswires · 05/12 16:27
Cyclo Therapeutics to Participate in the Virtual Investor Niemann-Pick Disease Type C Spotlight Event
GAINESVILLE, Fla., May 09, 2022--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a late clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and fa...
Business Wire · 05/09 12:05
4 Penny Stocks Insiders Are Buying
US crude oil futures traded sharply lower this morning on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and ...
Benzinga · 03/31 10:16
Cyclo Therapeutics to Participate in the Virtual Investor Alzheimer’s Disease Spotlight Event
GAINESVILLE, Fla., March 29, 2022--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a late clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and ...
Business Wire · 03/29 12:35
Cyclo Therapeutics Enters Research And Collaboration Agreement With Wits Commercial Enterprise To Explore Potential Applications Of Trappsol Cyclo To Expand Pipeline
Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a late clinical stage biotechnology company dedicated to developing life-changing medicines through science and
Benzinga · 03/24 12:06
Cyclo Therapeutics Enters Research and Collaboration Agreement with Wits Commercial Enterprise (Pty) Ltd to Explore Potential Applications of Trappsol® Cyclo™ to Expand Pipeline
GAINESVILLE, Fla., March 24, 2022--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a late clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and ...
Business Wire · 03/24 12:05
Cyclo Therapeutics Enters Research Pact with Wits University to Further Explore Trappsol Cyclo
MT Newswires · 03/24 10:21
Cyclo Therapeutics to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
GAINESVILLE, Fla., March 23, 2022--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and famil...
Business Wire · 03/23 12:25
Cyclo Therapeutics Earnings Perspective: Return On Capital Employed
According to data from Benzinga Pro, during Q4, Cyclo Therapeutics's (NASDAQ:CYTH) reported sales totaled $585.12 thousand. Despite a 27.66% increase in earnings, the company posted a loss of $2.79 million.
Benzinga · 03/15 15:09
Cyclo Therapeutics GAAP EPS of -$2.24 misses by $0.36, revenue of $1.58M misses by $0.48M
Cyclo Therapeutics press release (NASDAQ:CYTH): FY GAAP EPS of -$2.24 misses by $0.36. Revenue of $1.58M (+75.6% Y/Y) misses by $0.48M.
Seekingalpha · 03/14 12:17
Cyclo Therapeutics to Present at the Oppenheimer 32nd Annual Healthcare Conference
GAINESVILLE, Fla., March 10, 2022--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and famil...
Business Wire · 03/10 13:05
More
Webull provides a variety of real-time CYTH stock news. You can receive the latest news about Cyclo Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About CYTH
Cyclo Therapeutics, Inc. is a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease. The Company's lead drug candidate, Trappsol Cyclo (hydroxypropyl beta cyclodextrin) is for the treatment of Niemann-Pick Type C disease (NPC). NPC is a rare and fatal cholesterol metabolism disease that impacts the brain, lungs, liver, spleen, and other organs. It is also focusing on the use of cyclodextrins in the treatment of Alzheimer's disease. The Company's product lines include Trappsol and Aquaplex. It sells its chemical products directly to customers in the pharmaceutical, diagnostics, and industrial chemical industries, and to chemical supply distributors. The Company also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs.